Abstract
The objective of this study was to determine whether prodynorphin-derived opioid peptides could block the spontaneous luteinizing hormone (LH) surge and ovulation, and if so, whether this inhibitory action was mediated through κ-opioid receptors. Various doses of dynorphin peptides (dynorphin A1–17, dynorphin A1–8, dynorphin B, α- and β-neoendorphin) were infused into the brain through third-ventricle cannulae in rats between 1330–1800 h on proestrus. Each dynorphin peptide blocked the LH surge and ovulation in a dose-dependent manner. Dynorphin A1–17 and A1–8 were equally effective in producing these actions, and more potent than either dynorphin B or α- or β-neoendorphin. U50,488H, a specific κ-opioid receptor agonist, also blocked the LH surge and ovulation. When a mixture of five dynorphin peptides was infused intraventricularly, each at a dose that inhibited the LH surge, both the surge and ovulation were blocked. However, when norbinaltorphimine, a specific κ-opioid receptor antagonist, was coinfused with the mixture of dynorphin peptides, the LH surge and ovulation were fully restored. These results demonstrate that prodynorphin-derived opioid peptides, acting through κ-opioid receptors, can block the LH surge and ovulation. Dynorphin A1–17 and A1–8 are the most potent in this regard.
Similar content being viewed by others
References
Kalra, S. P. (1993). Endocr. Rev. 14, 507–538.
Kalra, S. P. and Simpkins, J. W. (1981). Endocrinology 109, 776–782.
Leadem, C. A. and Kalra, S. P. (1985). Endocrinology 117, 684–689.
Maggi, R., Dondi, D., Rovati, G. E., Martini, L., Piva, F., and Limonta, P. (1993). Neuroendocrinology 58, 366–372.
Sarkar, D. K. and Yen, S. S. (1985). Endocrinology 116, 2075–2079.
Wise, P. M., Scarbrough, K., Weiland, N. G., and Larson, G. H. (1990). Mol. Endocrinol. 4, 886–892.
Smith, M. J. and Gallo, R. V. (1997). Brain Res. 768, 111–119.
Chavkin, C. and Goldstein, A. (1981). Proc. Natl. Acad. Sci. USA 78, 6543–6547.
Chavkin, C., James, I. F., and Goldstein, A. (1982). Science 215, 413–415.
Cone, R. I., Weber, E., Barchas, J. D., and Goldstein, A. (1983). J. Neurosci. 3, 2146–2152.
Seizinger, B. R., Grimm, C., Hollt, V., and Herz, A. (1984). J. Neurochem. 42, 447–457.
Weber, E., Evans, C. J., and Barchas, J. D. (1982). Nature 299, 77–79.
Zamir, N., Weber, E., Palkovits, M., and Brownstein, M. (1984). Proc. Natl. Acad. Sci. USA 81, 6886–6889.
James, I. F., Fischli, W., and Goldstein, A. (1984). J. Pharmacol. Exp. Ther. 228, 88–93.
Hollt, V. (1986). Annu. Rev. Pharmacol. Toxicol. 26, 59–77.
Cicero, T. J., Meyer, E. R., Miller, B. T., and Bell, R. D. (1988). J. Pharmacol. Exp. Ther. 246, 14–20.
Gilbeau, P. M., Hosobuchi, Y., and Lee, N. M. (1987). Neuroendocrinology 45, 284–289.
Pfeiffer, D. G., Pfeiffer, A., Shimohigashi, Y., Merriam, G. R., and Loriaux, D. L. (1983). Peptides 4, 647–649.
Walsh, J. P. and Clarke, I. J. (1996). Endocrinology 137, 3640–3648.
Kinoshita, F., Nakai, Y., Katakami, H., and Imura, H. (1982). Life Sci. 30, 1915–1919.
Leadem, C. A. and Kalra, S. P. (1985). Neuroendocrinology 41, 342–352.
Leadem, C. A. and Yagenova, S. V. (1987). Neurodocrinology 45, 109–117.
Marko, M. and Romer, D. (1983). Life Sci. 33, 233–240.
Almeida, O. F., Nikolarakis, K. E., Webley, G. E., and Herz, A. (1988). FASEB J. 2, 2874–2877.
Gallo, R. V. (1990). J. Neuroendocrinol. 2, 685–691.
Panerai, A. E., Petraglia, F., Sacerdote, P., and Genazzani, A. R. (1985). Endocrinology 117, 1096–1099.
Schulz, R., Wilhelm, A., Pirke, K. M., Gramsch, C., and Herz, A. (1981). Nature 294, 757–759.
Zhen, S. and Gallo, R. V. (1992). Endocrinology 131, 1650–1656.
Zhen, S. and Gallo, R. V. (1994). Brain Res. 642, 178–184.
Portoghese, P. S., Lipkowski, A. W., and Takemori, A. E. (1987). Life Sci. 40, 1287–1292.
Tortella, F. C., Echevarria, E., Lipkowski, A. W., Takemori, A. E., Portoghese, P. S., and Holaday, J. W. (1989). Life Sci. 44, 661–665.
Hewlett, W. A. and Barchas, J. D. (1983). Peptides 4, 853–858.
Quirion, R. and Pert, C. B. (1981). Eur. J. Pharmacol. 76, 467, 468.
Zhang, S., Tong, Y., Tian, M., Dehaven, R. N., Cortesburgos, L., Mansson, E., Simonin, F., Kieffer, B., and Yu, L. (1998). J. Pharmacol. Exp. Ther. 286, 136–141.
Massardier, D. and Hunt, P. F. (1989). Eur. J. Pharmacol. 170, 125, 126.
Skilling, S. R., Sun, X., Kurtz, H. J., and Larson, A. A. (1992). Brain Res. 575, 272–278.
Cacicedo, L., Sanchez Franco, F. (1986). Life Sci. 38, 617–625.
Chao, C. C., Moss, G. E., and Malven, P. V. (1986). Life Sci. 39, 527–534.
Blank, M. S., Fabbri, A., Catt, K. J., and Dufau, M. L. (1986). Endocrinology 118, 2097–2101.
Cicero, T. J., Schainker, B. A., and Meyer, E. R. (1979). Endocrinology 104, 1286–1291.
Wiesner, J. B., Koenig, J. I., Krulich, L., and Moss, R. L. (1984). Life Sci. 34, 1463–1473.
Cicero, T. J., Wilcox, C. E., Bell, R. D., and Meyer, E. R. (1980). J. Pharmacol. Exp. Ther. 212, 573–578.
Ferin, M., Wehrenberg, W. B., Lam, N. Y., Alston, E. J., and Vande Wiele, R. L. (1982). Endocrinology 111, 1652–1656.
Mansour, A., Burke, S., Pavlic, R. J., Akil, H., and Watson, S. J. (1996). Neuroscience 71, 671–690.
Kalra, P. S., Crowley, W. R., and Kalra, S. P. (1987). Endocrinology 120, 178–185.
Leadem, C. A., Crowley, W. R., Simpkins, J. W., and Kalra, S. P. (1985). Neuroendocrinology 40, 497–500.
Wilkes, M. M. and Yen, S. S. (1981). Life Sci. 28, 2355–2359.
Rasmussen, D. D., Liu, J. H., Wolf, P. L., and Yen, S. S. (1983). J. Clin. Endocrinol. Metab. 57, 881–884.
Fallon, J. H. and Leslie, F. M. (1986). J. Comp. Neurol. 249, 293–336.
Khachaturian, H., Watson, S. J., Lewis, M. E., Coy, D., Goldstein, A., and Akil, H. (1982). Peptides 3, 941–954.
Neal, C. R. Jr. and Newman, S. W. (1989). J. Comp. Neurol. 288, 353–386.
Simerly, R. B., McCall, L. D., and Watson, S. J. (1988). J. Comp. Neurol. 276, 442–459.
Vincent, S. R., Hokfelt, T., Christensson, I., and Terenius, L. (1982). Neurosci. Lett. 33, 185–190.
Desjardins, G. C., Brawer, J. R., and Beaudet, A. (1990). Brain Res. 536, 114–123.
Mansour, A., Khachaturian, H., Lewis, M. E., Akil, H., and Watson, S. J. (1988). Trends Neurosci. 11, 308–314.
Witkin, J. W., Paden, C. M., and Silverman, A. J. (1982). Neuroendocrinology 35, 429–438.
Zhen, S. and Gallo, R. V. (1995). Brain Res. 698, 121–129.
Maggi, R., Pimpinelli, F., Martini, L., and Piva, F. (1995). Endocrinology 136, 289–295.
Mitchell, V., Prevot, V., Jennes, L., Aubert, J. P., Croix, D., and Beauvillain, J. C. (1997). Neuroreport 8, 3167–3172.
Sannella, M. I. and Petersen, S. L. (1997). Endocrinology 138, 1667–1672.
Pugh, G. Jr., Mason, D. J. Jr., Combs, V., and Welch, S. P. (1997). J. Pharmacol. Exp. Ther. 281, 730–737.
Corbett, A. D., Paterson, S. J., McKnight, A. T., Magnan, J., and Kosterlitz, H. W. (1982). Nature 299, 79–81.
Sandin, J., Tan-No, K., Kasakov, L., Nylander, I., Winter, A., Silberring, J., and Terenius, L. (1997). Peptides 18, 949–956.
Mansour, A., Hoversten, M. T., Taylor, L. P., Watson, S. J., and Akil, H. (1995). Brain Res. 700, 89–98.
Xue, J. C., Chen, C., Zhu, J., Kunapuli, S., DeRiel, J. K., Yu, L., and Liu-Chen, L. Y. (1994). J. Biol. Chem. 269, 30,195–30,199.
Zhang, Q. and Gallo, R. V. (2001). Soc. Neurosci. Abstr. 630.5.
deGroot, J. (1959). In: The rat forebrain in stereotaxic coordinates. North-Holland Publishers: Amsterdam.
Vonvoigtlander, P. F., Lahti, R. A., and Ludens, J. H. (1983). J. Pharmacol. Exp. Ther. 224, 7–12.
Niswender, G. D., Midgley, A. R. Jr., Monroe, S. E., and Reichert, L. E. Jr. (1968). Proc. Soc. Exp. Biol. Med. 128, 807–811.
Gallo, R. V. (1981). Biol. Reprod. 24, 771–777.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, Q., Gallo, R.V. Effect of prodynorphin-derived opioid peptides on the ovulatory luteinizing hormone surge in the proestrous rat. Endocr 18, 27–32 (2002). https://doi.org/10.1385/ENDO:18:1:27
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/ENDO:18:1:27